321 results on '"Deeg, H. Joachim"'
Search Results
2. Risk prediction for clonal cytopenia: multicenter real-world evidence
3. Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study
4. How I reduce and treat posttransplant relapse of MDS
5. Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
6. JAK2V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes
7. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial
8. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
9. Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation
10. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
11. Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis
12. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase
13. Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study
14. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation
15. Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience
16. Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in Adults
17. Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia
18. Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study
19. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity
20. Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
21. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
22. Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome
23. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes
24. Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders
25. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents
26. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial
27. Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin
28. Disruption of Iron Regulation after Radiation and Donor Cell Infusion
29. Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome
30. Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups
31. Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure
32. Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing
33. Quantitative analysis of glycans, related genes, and proteins in two human bone marrow stromal cell lines using an integrated strategy
34. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
35. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
36. Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial
37. Role of Hematopoietic Stem Cell Transplantation in Patients with Myeloproliferative Disease
38. α-1-Antitrypsin (AAT)–modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics
39. Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis
40. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality
41. Murine xenogeneic models of myelodysplastic syndrome: An essential role for stroma cells
42. Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
43. JAK2 V617F Mutation and Associated Chromosomal Alterations Involving JAK2 in Pre-HCT Blood Samples and Transplant Outcomes in Myelofibrosis Subtypes
44. Allogeneic Transplantation, Fas Signaling, and Dysregulation of Hepcidin
45. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita
46. Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes
47. Allogeneic hematopoietic cell transplantation for MDS: For whom, when and how?
48. Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
49. Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia
50. HLA-Matched Sibling Transplantation for Severe Aplastic Anemia: Impact of HLA DR15 Antigen Status on Engraftment, Graft-versus-Host Disease, and Overall Survival
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.